Stay updated on Resmetirom in NASH and Fibrosis Clinical Trial

Sign up to get notified when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Resmetirom in NASH and Fibrosis Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.8%
    Check dated 2025-02-20T12:56:55.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The website has updated to revision v2.14.2, and users may experience performance issues due to heavy traffic on some NLM-NCBI services and products.
    Difference
    0.8%
    Check dated 2025-02-06T06:44:59.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.0 to v2.14.1.
    Difference
    0.0%
    Check dated 2025-01-15T18:34:23.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.
    Difference
    0.1%
    Check dated 2025-01-08T12:49:56.000Z thumbnail image
  9. Check
    91 days ago
    Change Detected
    Summary
    A new Phase 3 clinical trial has been added to evaluate the efficacy and safety of MGL-3196 (Resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and fibrosis, with a focus on its potential to resolve NASH and prevent progression to cirrhosis.
    Difference
    100%
    Check dated 2024-12-24T23:44:02.000Z thumbnail image
  10. Check
    98 days ago
    Change Detected
    Summary
    A new Phase 3 clinical trial has been added to evaluate the efficacy and safety of MGL-3196 (Resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and fibrosis, while extensive details about previous studies and their results have been removed.
    Difference
    92%
    Check dated 2024-12-17T13:50:18.000Z thumbnail image

Stay in the know with updates to Resmetirom in NASH and Fibrosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.